Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

Item

http://www.wikidata.org/entity/Q43525106

Q43525106

about

Anti-nerve growth factor in pain management: current evidence Pain management with acupuncture in osteoarthritis: a systematic review and meta-analysis Future directions for the management of pain in osteoarthritis Towards a mechanism-based approach to pain management in osteoarthritis A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain Design and nuclear magnetic resonance (NMR) structure determination of the second extracellular immunoglobulin tyrosine kinase A (TrkAIg2) domain construct for binding site elucidation in drug discovery.Efficacy of Direct Injection of Etanercept into Knee Joints for Pain in Moderate and Severe Knee Osteoarthritis.Monoclonal antibodies for the treatment of osteoarthritis.Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.Osteoarthritis year in review 2015: clinical.Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration Mechanisms and Mediators That Drive Arthritis Pain.Investigational drugs for the treatment of osteoarthritis.Transmission pathways and mediators as the basis for clinical pharmacology of pain.Tanezumab in the treatment of chronic musculoskeletal conditions.Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.Efficacy of nerve growth factor antibody in a knee osteoarthritis pain model in mice.[EXPRESS] Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications.SEOM clinical guideline for treatment of cancer pain (2017).Native joint-resident mesenchymal stem cells for cartilage repair in osteoarthritis.First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.

P2860

Q26746194-E7CD0052-AC52-4AB6-8391-308C8A5F6BB2 Q27497186-0D568838-9C18-482A-A556-CAC97F07C55B Q33874031-D0C022B8-659A-4B1A-B0C1-1153CCB2D63E Q34120813-61F61152-D8CC-4799-AE1E-54827E95F399 Q35568842-F5B9918A-F70B-48D7-88F9-735FBC4707E2 Q35858432-0DB32BF1-AEFF-446E-93C0-944E0F4C4226 Q35971140-800F31C3-6753-46B9-BB15-12CF0396D28F Q36113839-97494F5E-1151-4771-8926-B2B8F00F32CF Q36236043-70CFF264-B21C-4DCA-80F1-5496D4E1E333 Q36409343-D9741342-2A68-4F1E-9BDA-AD21F684B52E Q36818355-1A84FD50-9878-4CA6-8215-5D650759E72F Q38508116-0DDAC831-6DD2-44FF-B0AB-20CF74ABF68A Q38597565-817A2A5E-1E21-4DEB-847D-DA6765DD0EA2 Q38870522-557A78F1-3821-4004-82AC-25E439A675FD Q39034462-6522905F-3F58-4882-838D-0D4C33AA0C4C Q39209120-5C2F6BD7-7B64-4A14-8C9C-01A325C5AD56 Q39210251-B8C0DDA6-4E8B-4BD0-A304-06BD589E7D52 Q45907144-412EFF89-489F-43A1-B16D-352DB4A846D1 Q46156381-34562D42-6C63-4D7D-8953-D42480FDE806 Q47285618-09BCF9EE-BF97-44F3-8150-A1CB95E8DF2E Q47629559-96BA654F-5E40-42B5-B5A9-0C93F1381684 Q55264146-BEDEF015-D66B-42AA-8371-C6C43BB9872E

P2860

Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

Item

http://www.wikidata.org/entity/Q43525106

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Efficacy and safety of tanezum ...... III randomised clinical trial.

@en

Efficacy and safety of tanezum ...... III randomised clinical trial.

@nl

type

Item

label

Efficacy and safety of tanezum ...... III randomised clinical trial.

@en

Efficacy and safety of tanezum ...... III randomised clinical trial.

@nl

prefLabel

Efficacy and safety of tanezum ...... III randomised clinical trial.

@en

Efficacy and safety of tanezum ...... III randomised clinical trial.

@nl

P1476

Efficacy and safety of tanezum ...... III randomised clinical trial.

@en

P2093

Andra Rodica Balanescu

http://www.w3.org/2001/XMLSchema#string

Christine R West

http://www.w3.org/2001/XMLSchema#string

Eugen Feist

http://www.w3.org/2001/XMLSchema#string

Gernot Wolfram

http://www.w3.org/2001/XMLSchema#string

Isabelle Davignon

http://www.w3.org/2001/XMLSchema#string

Mark T Brown

http://www.w3.org/2001/XMLSchema#string

Michael D Smith

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

Radiological assessment of osteo-arthrosis

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.

Novel class of pain drugs based on antagonism of NGF.

Targeting nerve growth factor in pain: what is the therapeutic potential?

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.

Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.

Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing.

P304

1665-1672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2012-203164

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23852695

http://www.w3.org/2001/XMLSchema#string

P921

diclofenac

placebo

phase III clinical trial

osteoarthritis

Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

about

P2860

P2860

Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921